Twist Bioscience Corporation Liabilities Assumed
Twist Bioscience Corporation (TWST) reported Liabilities Assumed of $487.00 thousand for the 3-month period ending 2023-12-31, per its 10-Q filed 2024-02-02.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2024-02-02
- Twist Bioscience Corporation liabilities assumed for the quarter ending 2023-12-31 was $487.00K, a 89.23% decline year-over-year.
- Twist Bioscience Corporation liabilities assumed for the quarter ending 2023-09-30 was -$914.00K.
- Twist Bioscience Corporation liabilities assumed for the quarter ending 2023-06-30 was -$61.00K.
- Twist Bioscience Corporation liabilities assumed for the quarter ending 2023-03-31 was -$2.77M.
- Twist Bioscience Corporation liabilities assumed for fiscal 2023 was $772.00K, a 87.74% decline from fiscal 2022.
- Twist Bioscience Corporation liabilities assumed for fiscal 2022 was $6.30M, a 213.13% increase from fiscal 2021.
- Twist Bioscience Corporation liabilities assumed for fiscal 2021 was $2.01M, a 50.86% increase from fiscal 2020.
- Twist Bioscience Corporation liabilities assumed for fiscal 2020 was $1.33M, a 684.12% increase from fiscal 2019.
| Period end | Liabilities Assumed 3 month | Liabilities Assumed 6 month | Liabilities Assumed 9 month | Liabilities Assumed 12 month |
|---|---|---|---|---|
| 2023-12-31 | $487.00K 10-Q · filed 2024-02-02 | -$427.00K derived: sum of 2 quarters · filed 2024-02-02 | -$488.00K derived: sum of 3 quarters · filed 2024-02-02 | -$3.26M derived: sum of 4 quarters · filed 2024-02-02 |
| 2023-09-30 | -$914.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | -$975.00K derived: sum of 2 quarters · filed 2023-11-21 | -$3.75M derived: sum of 3 quarters · filed 2023-11-21 | $772.00K 10-K · filed 2023-11-21 |
| 2023-06-30 | -$61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | -$2.83M derived: sum of 2 quarters · filed 2023-08-07 | $1.69M 10-Q · filed 2023-08-07 | $1.42M derived: sum of 4 quarters · filed 2024-02-02 |
| 2023-03-31 | -$2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-08 | $1.75M 10-Q · filed 2023-05-08 | $1.48M derived: sum of 3 quarters · filed 2024-02-02 | -$693.00K derived: sum of 4 quarters · filed 2024-02-02 |
| 2022-12-31 | $4.52M 10-Q · filed 2024-02-02 | $4.25M derived: sum of 2 quarters · filed 2024-02-02 | $2.08M derived: sum of 3 quarters · filed 2024-02-02 | -$662.00K derived: sum of 4 quarters · filed 2024-02-02 |
| 2022-09-30 | -$265.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | -$2.44M derived: sum of 2 quarters · filed 2023-11-21 | -$5.18M derived: sum of 3 quarters · filed 2023-11-21 | $6.30M 10-K · filed 2023-11-21 |
| 2022-06-30 | -$2.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | -$4.92M derived: sum of 2 quarters · filed 2023-08-07 | $6.56M 10-Q · filed 2023-08-07 | $6.80M derived: sum of 4 quarters · filed 2023-11-21 |
| 2022-03-31 | -$2.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-08 | $8.74M 10-Q · filed 2023-05-08 | $8.97M derived: sum of 3 quarters · filed 2023-11-21 | $10.55M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-12-31 | $11.48M 10-Q · filed 2023-02-07 | $11.71M derived: sum of 2 quarters · filed 2023-11-21 | $13.29M derived: sum of 3 quarters · filed 2023-11-21 | $11.97M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-09-30 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $1.81M derived: sum of 2 quarters · filed 2023-11-21 | $496.00K derived: sum of 3 quarters · filed 2023-11-21 | $2.01M 10-K · filed 2023-11-21 |
| 2021-06-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | $262.00K derived: sum of 2 quarters · filed 2022-08-08 | $1.78M 10-Q · filed 2022-08-08 | $3.09M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | -$1.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-06 | $197.00K 10-Q · filed 2022-05-06 | $1.51M derived: sum of 3 quarters · filed 2023-06-05 | $756.00K derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | $1.51M 10-Q · filed 2022-02-09 | $2.83M derived: sum of 2 quarters · filed 2023-06-05 | $2.07M derived: sum of 3 quarters · filed 2023-06-05 | $2.78M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | $1.31M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $559.00K derived: sum of 2 quarters · filed 2023-06-05 | $1.27M derived: sum of 3 quarters · filed 2023-06-05 | $1.33M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | -$752.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09 | -$44.00K derived: sum of 2 quarters · filed 2021-08-09 | $22.00K 10-Q · filed 2021-08-09 | -$1.08M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | $708.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-07 | $774.00K 10-Q · filed 2021-05-07 | -$329.00K derived: sum of 3 quarters · filed 2021-11-23 | $758.00K derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | $66.00K 10-Q · filed 2021-02-09 | -$1.04M derived: sum of 2 quarters · filed 2021-11-23 | $50.00K derived: sum of 3 quarters · filed 2021-11-23 | -$881.00K derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-09-30 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | -$16.00K derived: sum of 2 quarters · filed 2021-11-23 | -$947.00K derived: sum of 3 quarters · filed 2021-11-23 | $170.00K 10-K · filed 2021-11-23 |
| 2019-06-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-12 | $156.00K derived: sum of 2 quarters · filed 2020-08-12 | $1.27M 10-Q · filed 2020-08-12 | |
| 2019-03-31 | -$931.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-13 | $186.00K 10-Q · filed 2020-05-13 | ||
| 2018-12-31 | $1.12M 10-Q · filed 2020-02-10 | |||
| 2018-09-30 | $344.00K 10-K · filed 2020-11-27 | |||
| 2018-03-31 | -$202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-02 | $24.00K 10-Q · filed 2019-05-02 | ||
| 2017-12-31 | $226.00K 10-Q · filed 2019-02-11 | |||
| 2017-09-30 | $285.00K 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |